MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2023 International Congress

August 27-31, 2023. Copenhagen, Denmark.

View by Title View Categories
Jump to:  View All • [a] b c d e f g h i j k l m n o p q r s t u v w x y z
  • A 10-year service evaluation of a Cervical Dystonia Botulinum Toxin A Clinic: Factors associated with a patient satisfaction.

    M. Bradley, M. Ryan, F. Molloy (Dublin, Ireland)

  • A 16-week open-label study of the effects of treatment with pimavanserin on activities of daily living in subjects with Parkinson’s disease psychosis (PDP)

    V. Evidente, D. Dekarske, B. Coate, V. Abler (Scottsdale, USA)

  • A 20-Year Follow-Up Case Report with Three DaT-SPECT Scans in Parkinson’s Disease Diagnosis

    S. Virameteekul, K. Bhatia (London, United Kingdom)

  • A 20-year review of a Movement Disorders Database in Singapore

    YH. Nah, S. Neo, S. Ng, N. Chia, HL. Ng, W. Li, A. Zhan, KY. Tay, Z. Xu, WL. Au, L. Tan (Singapore, Singapore)

  • A 78-year-old man with progressive ataxia, palatal tremor, parkinsonism and motor neuron disease.

    P. Hoang, JR. Zuzuarregui (San Francisco, USA)

  • A baseline study for the first year of a diverse Parkinson’s Disease interdisciplinary clinic

    V. Armengol, M. Sarno, M. Feldman, S. Marmol, A. Alfonso, G. Dumenigo, M. Garcia-Casals, S. Munzesheimer, A. Otto, TW. Siu, D. Shpiner (Miami, USA)

  • A benign course of Parkinson’s disease associated with different mutations in the glucocerebrosidase gene – a case series

    G. Yahalom, A. Faust-Socher, M. Cohen, Y. Schechter, M. Becker-Cohen, R. Eichel, S. Revel-Vilk, A. Zimran (Jerusalem, Israel)

  • A case of dystonia-predominant spinocerebellar ataxia type 3 treated with bilateral deep brain stimulation to the globus pallidus internal segment

    D. Rodriguez Gomez, B. Dalm, V. Khurana, C. Goas, Z. Jordan, B. Changizi (Boston, USA)

  • A case of idiopathic lower limb dystonia treated with combined use of botulinum toxin type A and phenol nerve block

    E. Bianchini, A. Massimiani, J. Bemporad, M. Giovannelli (Rome, Italy)

  • A Case of Post-malaria neurological syndrome presenting with tremor

    JS. Lee, JH. Ahn, JY. Youn, JH. Cho (Seoul, Republic of Korea)

  • A case of progressive ataxia with palatal tremor (PAPT) syndrome due to idiopathic bilateral hypertrophic olivary degeneration

    D. E, S. Kumar, A. Antony, J. Kumar (Kozhikode, India)

  • A case of trichotillomania as the preceding symptom of Huntington’ s diseaseand the effect of risperidone

    Y. Degirmenci, N. Bicak (Istanbul, Turkey)

  • A clinical and neurophysiological study of movement disorders in Wilson’s disease

    A. Gravier, MA. Obadia, JL. Thibault, A. Poujois, N. Kubis (Paris, France)

  • A clinical case of subdural hematoma caused by a tic-like head banging in a patient with neurodevelopmental disorder

    R. Almeida Paroni, F. Boscaini, A. Crucianelli, L. Zoccante (Verona, Italy)

  • A comparative analysis of vegetative disorders in Parkinson`s disease and vascular parkinsonism.

    R. Juraev, R. Matmurodov, K. Khalimova (Tashkent, Uzbekistan)

  • A comparative study of non-motor symptoms in Huntington’s disease and Parkinson’s disease

    WZ. Hu, JH. Yin, LX. Cao, Y. Huang (Beijing, China)

  • A Comparison of Cervical Dystonia in Parkinson’s Disease and Idiopathic Isolated Cervical Dystonia

    L. Higginbotham, S. Perez Parra, L. Scorr, H. Jinnah, S. Factor (Atlanta, USA)

  • A comparison of national data on Parkinson’s disease mortality between the USA and UK

    N. Smati, W. Lintiso, E. Shamim (Gaithersburg, USA)

  • A cross regional investigation into the effects of fractures on the quality of life for elderly people with Parkinson’s disease in rural India

    S. Kuanar, C. Mahapatra (Bhubaneswar, India)

  • A cross-sectional study of telemedicine use during the COVID-19 pandemic in people with Parkinson’s disease

    A. Patel, R. Schuldt, D. Boudreau, N. Win, B. Cobb, M. Mcginley (South San Francisco, USA)

  • A digital differential diagnostic aid for Parkinson’s disease and other tremor disorders

    C. Papasavvas, D. Bramwell, R. Zietsma, A. Deutschlander, R. Walker (Edinburgh, United Kingdom)

  • A family of Huntington’s disease with genetic anticipation in its paternal inheritance

    KY. Park, S. Jo, S. Lee, J. Lee, SJ. Chung (Daejeon, Republic of Korea)

  • A forgotten cause of ocular motor apraxia

    C. Azoia, C. Silva, A. Velon, A. Raimundo (Vila Real, Portugal)

  • A framework to standardize gait study protocols in Parkinson’s disease

    M. Mancini, J. Hausdorff, E. Pelosin, P. Bonato, R. Camicioli, T. Ellis, J. Klucken, L. Gifford, A. Fasano, A. Nieuwboer, K. Kopil, K. Klapper, A. Mirelman (Portland, USA)

  • A human tissue engineered nigrostriatal system as a testbed for understanding PD pathophysiology and therapeutic development

    D. Chouhan, K. Browne, R. Patel, S. Karandikar, F. Laimo, D. Cullen, J. Duda (Philadelphia, USA)

  • A juvenile onset Sandhoff disease case caused by hemizygous mutations of HEXB

    JH. Yin (Beijing, China)

  • A minimal clinically important difference for UHDRS® Total Maximal Chorea score as a measure of chorea severity in Huntington disease

    E. Furr Stimming, D. Claassen, E. Kayson, J. Goldstein, H. Zhang, O. Klepitskaya, G. Liang, D. Haubenberger (Houston, USA)

  • A multicenter, matched case-control study of alpha-synuclein accumulation in the gastrointestinal tract of Parkinson’s disease

    C. Shin, S. Kim, SH. Park, JM. Kim, JY. Lee, SJ. Chung, JW. Kim, TB. Ahn, KW. Park, JH. Shin, CY. Lee, HJ. Lee, SH. Kong, YS. Suh, HK. Yang, HJ. Kim, B. Jeon (Sejong-si, Republic of Korea)

  • A multimodal approach for diagnosis of early Multiple System Atrophy (MSA)

    D. Claassen, J. Iregui, P. Trujillo, A. Wynn, C. Wong, M. Bradbury, D. Stamler (Nashville, USA)

  • A multiple-dose thorough QT study to evaluate the effect of ampreloxetine on cardiac repolarization in healthy subjects

    M. Borin, J. Kanodia, R. Graham, A. Lo, B. Zheng, D. Bourdet (South San Francisco, USA)

  • A Need for Improving the Diet Quality of Individuals with Parkinson’s Disease

    S. Mandali, K. Lyons, R. Pahwa, A. Lee (Kansas City, USA)

  • A network imaging biomarker of X-linked dystonia-parkinsonism

    M. Niethammer, C. Tang, R. Jamora, A. Vo, N. Nguyen, Y. Ma, S. Peng, J. Waugh, D. Eidelberg (Manhasset, USA)

  • A new era in etiologies of chorea

    D. Biederko, M. Bennun Caller, L. Franken, R. Djaldetti (Petah Tikva, Israel)

  • A new synchronization method between inertial signals and local field potentials

    I. D'Ascanio, G. Giannini, L. Baldelli, I. Cani, A. Giannoni, G. Leogrande, G. Lopane, G. Calandra-Buonaura, P. Cortelli, L. Chiari, L. Palmerini (Bologna, Italy)

  • A newly implemented NGS-based method to detect GBA1 variants in patients with Parkinson’s disease

    E. Monfrini, I. Palmieri, G. Cuconato, M. Percetti, P. Cortelli, A. Di Fonzo, EM. Valente (Milano, Italy)

  • A non-expensive bidimensional assessment can detect subtle alterations in gait performance in people in the early stages of Parkinson’s disease

    M. Pimentel Piemonte, M. Dalencar, G. Venas, A. Helene, A. Roque, J. Vivas (Sao Paulo, Brazil)

  • A novel missense variant in the TTBK2 gene in a north American family with late-onset cerebellar ataxia.

    O. Halhouli, P. Natteru, T. Grider, C. Groth (Iowa City, USA)

  • A novel mobile application for monitoring the response to botulinum toxin in patients with Cervical Dystonia.

    M. Bradley, C. Edwards, R. Borton, A. Ross, F. Molloy (Dublin, Ireland)

  • A novel model of care for an integrated movement assessment program (I-MAP) targeted for patients with movement disorders

    V. Balasubramaniam (Wollongong, Australia)

  • A novel motor-learning based dysphagia treatment approach in Parkinson’s disease

    E. Wang, L. Verhagen Metman (Chicago, USA)

  • A Novel Real Time Algorithm to Predict Freezing of Gait in Parkinson’s Patients Using Wearable Mobility Sensors Data

    N. Galor, T. Krasovsky, S. Hassin, B. Heimler, M. Plotnik (Ramat Gan, Israel)

  • A novel THAP1 variant presenting with early-onset generalized dystonia in a family

    A. Dellert, B. Rodrigues, N. Prakash (Farmington, USA)

  • A novel truncating variant in UBAP1 gene causing hereditary spastic paraplegia type 80

    S. Koya Kutty, MN. Zainal Anuar, SA. Abu Hassan, FM. Magrinelli, KB. Bhatia (Kuantan, Malaysia)

  • A novel, population-specific PINK1 p.F385S loss of function mutation in an Indian family with Parkinson’s disease

    K. Sharma, A. Kishore, A. Lechado, F. Raimondi, M. Sturm, A. Ashok-Kumar-Sreelatha, D. Kalikavil-Puthenveedu, G. Sarma, N. Casadei, R. Krüger, T. Gasser, P. Kahle, O. Riess, J. Fitzgerald, M. Sharma (Tübingen, Germany)

  • A Parkinson Shoe with Combined Plantar Pressure and Vibratory Stimulation in Parkinson’s Disease Patients with Freezing of Gait: A Randomized Controlled Trial with Plantar Pressure Analysis

    W. Phuenpathom, P. Panyakaew, P. Vateekul, D. Surangsrirat, R. Bhidayasiri (Bangkok, Thailand)

  • A Parkinson’s Manifesto for Europe

    F. Montague, A. Hursey (Orpington, United Kingdom)

  • A Peruvian family with neurodegeneration with ataxia, dystonia and gaze palsy, childhood-onset (NADGP): A case report

    E. Sarapura-Castro, C. Chacaltana-Viñas, P. Ramirez-Pajares, A. Manrique-Palomino, A. Clause, A. Chawla, A. Rivera-Valdivia, J. Bazalar-Montoya, K. Milla-Neyra, E. Thorpe, M. Cornejo-Olivas (Lima, Peru)

  • A phase 2 randomized, double-blind, placebo-controlled trial of Ambroxol as a disease-modifying treatment for Parkinson’s disease dementia.

    S. Pasternak, C. Silveira, K. Coleman, R. Garcia, J. Wells, M. Borrie, P. Macdonald, R. Bartha, M. Jenkins, S. Morrow, D. Mendonca, G. Zou, E. Finger, T. Rupar, R. Tirona, M. Jog (London, Canada)

  • A Phase 2, Double-blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ABP-450 (PrabotulinumtoxinA) in Adults with Isolated Cervical Dystonia

    J. Jankovic, C. Oh, Y. Liu, C. Comella (Irvine, USA)

  • A pilot study to prepare patients for doctor’s consultation based on the NMS-Quest and a wearable medical device

    L. Carrasco, D. álvarez, M. Pérez, C. Capra, D. Rodriguez-Martin, M. Mata, M. Kurtis, C. Borrué, L. López-Manzanares (Madrid, Spain)

  • A pilot, randomized, placebo controlled, double-blinded, delayed start trial of Modafinil for the treatment of Freezing of Gait in Parkinson’s disease.

    T. Virmani, L. Pillai, R. Landes, A. Glover, M. Lotia, R. Dhall, E. Garcia-Rill (LITTLE ROCK, USA)

  • A portable and distributable measure of temporal discrimination: an objective means for diagnosis of cervical dystonia.

    SR. Bostan, C. Fearon, M. Hutchinson, R. Reilly (Dublin, Ireland)

  • A qualitative study exploring the feasibility of exergames among persons with Parkinson’s disease

    C. Chung, J. Poh, Z. Yee, S. Neo (Singapore, Singapore)

  • A randomised, double blind, placebo controlled, crossover trial of incobotulinum toxin A treatment for upper limb tremor

    S. Nagaratnam, D. Wilson, H. Morales Briceno, V. Fung (Westmead, Australia)

  • A randomized, phase 2a, double-blind, placebo-controlled clinical trial with NE3107 adjunctive to carbidopa/levodopa in patients with Parkinson’s disease

    J. Aldred, R. Rodriguez, E. Rivera-Rivera, S. Isaacson, R. Kumar, A. Ellenbogen, C. Ahlem, C. Reading, J. Palumbo, N. Osman, A. Lang (Spokane, USA)

  • A rare case of PDE10A associated dystonia with bilateral striatal lesions

    R. Vasireddy, T. Ali, Y. Zarate, Z. Guduru (Lexington, USA)

  • A retrospective comparison between EMG and US-guided botulinum injections for cervical dystonia

    V. Livneh, A. Socher, M. Cohen, Y. Schechter, I. Israel, T. Gurevic, G. Yahalom (Tel Aviv, Israel)

  • A retrospective comparison of functional and quality of life outcomes in DBS patients implanted via awake or asleep surgery: the Rush University Medical Center experience

    C. Swan, J. Mazza, V. Palakuzhy, M. Wedding, S. Ramos, N. Patel, S. Sani (Chicago, USA)

  • A Retrospective Review of Amantadine in Progressive Supranuclear Palsy

    N. Mcfarland, R. Farrukh, S. Mahn (Gainesville, USA)

  • A role of transcranial sonography in evaluating patients with dystonia and tremor

    č. Jovanović, I. Petrović, N. Dragašević Mišković, A. Pavlović, M. Mijajlović, M. Svetel (Belgrade, Serbia)

  • A single centre retrospective study of dual target deep brain stimulation for clinically complex essential and dystonic tremor – a 5-year follow up

    H. Shepherd, R. Heartshorne, J. Osman-Farah, A. Macerollo (Liverpool, United Kingdom)

  • A single session of aerobic exercise increase EEG gamma band in the motor and sensorimotor areas during usual walking in people with Parkinson’s disease

    D. Orcioli-Silva, R. Vitório, V. Beretta, A. Oliveira, N. Conceição, P. Nóbrega-Sousa, P. Santos, L. Gobbi, J. Barela (Rio Claro, Brazil)

  • A staged screening paradigm to identify people at risk of Parkinson’s disease in the Parkinson’s Progression Markers Initiative

    E. Brown, A. Siderowf, T. Simuni, T. Sherer, M. Brumm, C. Caspell-Garcia, R. Kurth, C. Gochanour, M. Kuhl, M. Korell, J. Valverde Twiggs, C. Stanley, L. Concha, C. Soto, K. Marek, C. Tanner (San Francisco, USA)

  • A strategic training framework for building research capacity in the Global Parkinson’s Genetics Program (GP2)

    MT. Periñan, S. Dey, C. Bale, M. Kuhl, H. Leonard, P. Lewis, S. Stott, MB. Makarious, A. Martinez-Carrasco, AJ. Noyce, S. Bandres-Ciga, GP2. Genetics Program (Seville, Spain)

  • A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data

    T. Nikolcheva, G. Pagano, N. Pross, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Seppi, A. Monnet, N. Shariati, L. Rutten-Jacobs, S. Zanigni, T. Kustermann, K. Taylor, D. Trundell, H. Svoboda, A. Bonni, P. Fontoura, R. Doody (BASEL, Switzerland)

  • A systematic review of Action Observation Therapy for Parkinson’s disease rehabilitation.

    A. Ibrahim Abdelhamed, H. Samy, M. Elafifi, R. Hesham, M. Walid, M. Salah, M. Mohamed, R. Fekry, S. Elwaly, M. Zakzok, M. Fahmy Mohamed, M. Agaiby Amin, A. Melad Sedarous, M. Shafiek Saleh (Elfashn, Egypt)

  • A Systematic Review of the Type, Timing, Frequency and Durability of Effect in Parkinson’s Disease Physical Therapy

    M. El Hayek, J. Jofili Lopes, J. Lelaurin, A. Abi Nehme, K. Au, M. Okun, R. Salloum (Gainesville, USA)

  • A tau-directed monoclonal antibody could alter the tau pathology of progressive supranuclear palsy

    G. Beck, R. Yamashita, Y. Yonenobu, K. Ikenaka, S. Murayama, H. Mochizuki (Suita city, Japan)

  • A validation study of the Mini-BESTest in a Spanish population with Parkinson’s disease.

    A. García Bustillo, F. Valiñas Sieiro, M. Allende Río, A. Olivares Gil, JL. Garrido Labrador, JM. Ramírez Sanz, M. Jahouh, A. Arnaiz González, JF. Díez Pastor, N. Mariscal, S. Calvo Simal, J. Rivadeneyra-Posadas, L. Simón Vicente, J. González Santos, JJ. González Bernal, JM. Gabriel Galán, E. Cubo (Burgos, Spain)

  • A vicious cycle of karyopherin abnormalities in synucleinopathies

    D. Sharipov, E. Bereczki, R. Killick, T. Hortobagyi, C. Troakes, D. Aarsland, F. Hirth (London, United Kingdom)

  • A white matter disease with blooming grey matter

    K. Kanojia, F. Mustafa, P. Mohapatra, A. Srivastava, D. Radhakrishnan (New delhi, India)

  • AAV5-miHTT gene therapy mediates sustained mutant huntingtin lowering in brain and cerebrospinal fluid of Huntington’s disease minipigs up to 5 years

    L. Van_der Bent, C. Brouwers, A. Stam, L. Spronck, J. Klíma, J. Juhásová, B. Levinská, S. Juhás, J. Motlík, M. Evers, Z. Ellederova, A. Valles (Amsterdam, Netherlands)

  • Aberrant brain plasticity in patients with Parkinson’s disease and levodopa-induced dyskinesias

    P. Sanginario, B. Angeloni, C. Piano, AR. Bentivoglio, R. Di Iorio, F. Bove, P. Calabresi (Rome, Italy)

  • Abnormal sense of agency is involved in myoclonus dystonia phenotype through a cerebellar impairment

    C. Tarrano, C. Gallea, M. Vidailhet, E. Roze, Y. Worbe (Paris, France)

  • Accelerated longitudinal brain atrophy in the ‘diffuse malignant’ Parkinson’s disease subtype

    SM. Fereshtehnejad, R. Moqadam, R. Postuma, M. Dadar, Y. Zeighami (Ottawa, Canada)

  • Accelerometric Classification of Resting and Postural Tremor in Essential Tremor and Parkinson’s Disease

    C. Hennen, T. Berger, GA. Brandt, JN. Strelow, H. Jergas, JC. Baldermann, MT. Barbe, JN. Petry-Schmelzer, TA. Dembek (Cologne, Germany)

  • Access-PD – a ‘next generation’ registry to accelerate Parkinson’s disease research

    Y. Chang, A. Noyce (London, United Kingdom)

  • Actigraphy wear compliance across CNS disorders

    J. Lavine, A. Pearlmutter, K. Momeni, R. Ellis (New York, USA)

  • Action- and emotion-related language abilities in Slovenian-speaking individuals with Parkinson’s disease – a background normative study

    ž. Drakulić Gorše, C. Manouilidou, M. Trošt (Ljubljana, Slovenia)

  • Active contact proximity to the CTT predicts initial therapeutic current requirement in DBS for ET: an application of 7T MRI

    S. Ikramuddin, A. Brinda, R. Butler, M. Hill, J. Aman, L. Schrock, S. Cooper, T. Palnitkar, R. Patriat, N. Harel, J. Matsumoto, J. Vitek, M. Johnson (Minneapolis, USA)

  • Acute laryngeal stridor in the emergency department: pandemic or additional sign?

    F. Gomes, C. Silva, D. Damas, I. Carvalho, I. Cunha, A. Brás, A. Morgadinho, F. Moreira (Coimbra, Portugal)

  • Acute movement disorder with atypical topography. Acute hemichorea secondary to cortical stroke.

    CJ. de Miguel-Sánchez, G. Lafuente-Gómez, R. Leal-Hidalgo, M. González-Sánchez (Madrid, Spain)

  • Acute-onset parkinsonism secondary to bilateral extrapontine myelinolysis of the basal ganglia: case report

    N. Sarhan (Zagazig, Egypt)

  • Adaptive Deep Brain Stimulation for Parkinson’s Disease: from tolerability to patient preference and clinical outcomes

    A. Nakajima, G. Oyama, Y. Shimo, H. Kamo, A. Umemura, H. Iwamuro, Y. Sekiguchi, A. Tsuchiya, T. Brionne, K. Noel, N. Hattori (Tokyo, Japan)

  • Addition contact with 10 Hz stimulation in the STN may improve stimulation-induced cognitive disturbances

    A. Boogers, M. Cohn, M. Bernstein, A. Fasano (Toronto, Canada)

  • Adequate hydration with personalized diet improves bowel function and mobility for people with Parkinson’s (PwP’s) on levodopa/carbidopa intestinal gel (LCIG) infusion therapy

    Y. Ben Mordechai, S. Israeli-Korn, O. Cohen, S. Hassin-Baer (Tel Hashomer, Israel)

  • Adult hippocampal neurogenesis-associated memory performance in people with Parkinson’s disease with and without cognitive impairment

    L. Batzu, A. Podlewska, J. Staunton, P. Tall, V. Leta, C. Kim, S. Thuret, K. Ray Chaudhuri (London, United Kingdom)

  • Adult onset cerebrotendinous xanthomatosis (CTX) with parkinsonism responding to bilateral subthalamic nucleus deep brain stimulation

    R. Tilney, N. Dingli, E. Said, L. Zrinzo, J. Aquilina (London, United Kingdom)

  • Adult onset neuronal Intranuclear Inclusion Disease (NIID) which initially presented with gait imbalance and fall

    E. Oh, S. Lee (Daejeon, Republic of Korea)

  • Advanced programming strategies in subthalamic DBS: Just a gimmick or well-established in clinical routine?

    C. Schedlich-Teufer, GA. Brandt, C. Hennen, H. Jergas, JC. Baldermann, JK. Steffen, P. Reker, V. Stopic, JN. Strelow, V. Visser-Vandewalle, TA. Dembek, JN. Petry-Schmelzer, MT. Barbe (Cologne, Germany)

  • Adverse Events of Opicapone Adjunctive Therapy in 60 Consecutive Patients

    T. Bo, Y. Hashimoto, T. Ichikawa (Saitama, Japan)

  • Age at Onset and Therapeutic Efficacy of Primidone in Essential Tremor Patients

    F. Jamal, G. Jackson, A. Sarwar, P. Mandava (Houston, USA)

  • Age-associated changes in the striatal proteins in aging Asian-Indians

    H J. Jyothi, A. Mahadevan, T C. Yasha, P. Alladi (Bengaluru, India)

  • Aging brain in Parkinson`s: A study through biomarkers

    V. Rama Raju (Hyderabad, India)

  • Agreement between Parkinson disease Home Diary and observer assessments before and after structured patient training

    C. Janz, J. Timpka, M. Löhle, A. Bremer, F. Gandor, G. Ebersbach, A. Storch, P. Odin (Lund, Sweden)

  • Agreement between swallow tail sign asymmetry and clinical laterality in Parkinson’s disease

    M. Rohonczi, G. Perlaki, G. Hernádi, N. Kovács (Pécs, Hungary)

  • AI-Guided Microelectrode Recording for GPi DBS in Parkinson’s disease

    J. Wong, S. Aghili-Mehrizi, R. Forghani, A. Babajani, M. Okun, C. Butson, R. Fang (Gainesville, USA)

  • Alopecia in females with young onset Parkinson’s Disease: an exploratory survey

    K. Fisher, E. Clifford, N. Piniella, A. Leder, R. Gallagher (Glen Head, USA)

  • Alterations in Cortico-basal ganglia Directed Connectivity in Parkinsonism and during Therapeutic STN DBS

    B. Mohanty, J. Wang, L. Johnson, J. Vitek (Minneapolis, USA)

  • Alterations of gait as an early marker of incipient alpha-synucleinopathy

    K-L. Weiß, S. Röttgen, A. Ophey, G. Fink, M. Sommerauer (Cologne, Germany)

  • Alterations of the Right Olfactory Orbitofrontal Cortex and olfactory impairment in Parkinson’s Disease

    L. Pesantez Pacheco, M. Saquib, D. Ehrlich, M. Hallett, S. Horovitz (Bethesda, USA)

  • Altered brain energetics in Parkinson’s Disease: a multimodal neuroimaging study

    C. Bevington, J-C. Cheng, R. Jayde-Williams, B. Pike, J. Mckenzie, A. Stoessl, V. Sossi (Vancouver, Canada)

  • Altered cognitive control processes in the prodromal phase of X-linked dystonia-parkinsonism (XDP)

    M. Heldmann, J. Steinhardt, J. Dy, A. Sprenger, J. Tantianpact, H. Hanssen, R. Tuazon, R. Rosales, A. Westenberger, J. Oropilla, N. Brüggemann, C. Diesta (Lübeck, Germany)

  • Altered nucleus accumbens functional connectivity precedes apathy in Parkinson’s disease

    L. Morris, S. Harrison, T. Melzer, J. Dalrymple-Alford, T. Anderson, M. Macaskill, C. Le Heron (Christchurch, New Zealand)

  • Alzheimer’s Disease Co-pathology and its Influence on Biofluid Biomarkers in Autopsied Subjects from the PPMI Study

    D. Coughlin, K. Hwang, E. Bayram, D. Galasko (San Diego, USA)

  • Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson’s disease.The AMBITIOUS Study Protocol

    F. Colucci, M. Avenali, R. de Micco, A. Bacila, S. Cerri, G. Cuconato, V. Franco, D. Franciotta, C. Ghezzi, M. Gastaldi, C. Galandra, G. Germani, P. Mitrotti, G. Ongari, I. Palmieri, M. Picascia, A. Pichiecchio, F. Esposito, M. Cirillo, F. Di Nardo, S. Aloisio, M. Siciliano, M. Fusar Poli, M. Stanziano, B. Garavaglia, F. Cazzaniga, C. Reale, I. Tramacere, S. Priori, P. Amami, S. Piacentini, MG. Bruzzone, M. Grisoli, F. Moda, R. Eleopra, A. Tessitore, EM. Valente, R. Cilia (Milan, Italy)

  • Amplifying or suppressing subthalamic beta oscillations in real-time in Parkinson’s disease using evoked interference deep brain stimulation (eiDBS): feasibility in the human

    D. Escobar, B. Campbell, S. Mesbah, L. Favi Bocca, J. Liao, R. Rammo, S. Nagel, A. Machado, K. Baker (Cleveland, USA)

  • Amyloid status differentiates synaptic loss and atrophy in Corticobasal Syndrome.

    N. Holland, G. Savulich, P. Jones, D. Whiteside, D. Street, M. Naessens, M. Malpetti, Y. Hong, T. Fryer, T. Rittman, E. Mulroy, F. Aigbirhio, K. Bhatia, J. O'Brien, J. Rowe (Cambridge, United Kingdom)

  • An acoustic-perceptual analysis of speech in clinical PSP phenotypes.

    G. Di Rauso, F. Cavallieri, A. Gessani, D. Fontanesi, S. Coniglio, V. Fioravanti, S. Contardi, E. Menozzi, S. Meletti, F. Antonelli, V. Rispoli, F. Valzania, C. Budriesi (Modena, Italy)

  • An Algorithmic Approach to Assessing Cognitive Functioning in Individuals with REM Sleep Behavior Disorder

    G. Schneider, A. Avidan, D. Bliwise, S. Criswell, E. During, J. Elliott, L. Forsberg, J-F. Gagnon, M. Howell, D. Huddleston, A. Keil, J. Lee-Iannotti, M. Lim, J. Mcleland, M. Miglis, E. Mignot, R. Postuma, C. Schenck, D. Shprecher, E. ST. Louis, A. Videnovic, B. Boeve, Y-E. Ju, J. Fields (Rochester, USA)

  • An analysis of gender differences in the clinical profile of Parkinson’s Disease patients

    M. Nasi, N. Cazzola, L. Weis, E. Fiorenzato, V. Cianci, F. Pistonesi, A. Antonini, R. Biundo (Padova, Italy)

  • An Analysis of Subgroups of Multiple System Atrophy Patients from Ampreloxetine Phase 3 Trials

    R. Freeman, I. Biaggioni, L. Norcliffe-Kaufmann, T. Guerin, R. Vickery, L. Manzanares, V. Iodice, M. Rudzińska-Bar, M. Pellecchia, H. Kaufmann (Boston, USA)

  • An atypical presentation of Multiple System Atrophy (MSA)

    M. Magriço, V. Ferreira, B. Meira, R. Barbosa, P. Bugalho (Lisboa, Portugal)

  • An elderly female with subacute cerebellar ataxia: A case report

    N. Pandey, A. Kumar, A. Ranjan (Patna, India)

  • An European-Canadian multinational evaluation of access to care in Parkinson disease: a patient perspective

    M. van Munster, E. Crighton, A. Sánchez-Ferro, J. Ferreira, R. Bouça, E. Ruzicka, D. Pedrosa, D. Grimes, T. Mestre (Marburg, Germany)

  • An evaluation of NBI-827104 for essential tremor: results from a randomized, double-blind, placebo-controlled, dose-escalation, crossover study

    C. de Cuba, L. Smits, P. Kremer, R-J. Doll, J. Heuberger, R. Helmich, A F. van Rootselaar, R. Elble, W. Ondo, L. Rees, N. Wedick, G. Liang, D. Haubenberger (Leiden, Netherlands)

  • An Exploration of the Psychosocial Impact of Receiving Treatment at a Sialorrhea Clinic for People with Parkinson’s Disease

    M. Vazirian Zadeh, J. Adenwalla, C. Marquis, B. Mohamed, C. Thomas, R. Lewis-Morton (Penarth, United Kingdom)

  • An IMU- based Objective Quantification Method for Bradykinesia Evaluation in Parkinson’s disease

    Y. Wu, H. Yu, Y. Fan, G. Zhang, L. Guan, H. Hao, L. Li (Beijing, China)

  • An in-vivo study of regional synaptic density loss in patients with Multiple System Atrophy using [11C]UCB-J PET molecular imaging.

    E. de Natale, A. Terry, H. Wilson, J. Verghese, G. Pagano, P. Khosropanah, M. Howard, H. Wright, L. Cashmore, L. Passamonti, M. Hutchison, K. Evans, Y. Lewis, E. Rabiner, M. Politis (London, United Kingdom)

  • An in-vivo study of the integrity of the nigrostriatal pathways in drug-naive Parkinson’s disease patients using [11C]PE2I PET and neuromelanin-Magnetic Resonance Imaging

    G. Pagano, H. Wilson, E. de Natale, F. Niccolini, S. Polychronis, T. Yousaf, R. Gunn, E. Rabiner, M. Mehta, M. Politis (Basel, Switzerland)

  • An Interesting Case of COVID-19 related Parkinsonism

    P. Bhatia, A. Ata, K. Bailey (Tampa, USA)

  • An international consensus statement for rehabilitation care in Parkinson’s disease

    J. Goldman, D. Volpe, T. Ellis, M. Hirsch, J. Johnson, J. Wood, A. Aragon, R. Biundo, A. Dirocco, G. Kasman, R. Iansek, J. Miyasaki, V. Mcconvey, M. Munneke, S. Pinto, K. St Clair, S. Toledo, M. York, R. Todaro, N. Yarab, K. Wallock (Chicago, USA)

  • An investigation of early changes in the brain due to mild cognitive impairment in Parkinson’s disease

    N. Saadat, E. Mazerolle, J. Gawryluk (Victoria, Canada)

  • An objective shortened 5-item smell test: determinants of performance and agreement with subjective assessment

    Z. Markovic-Obiago, J. Bestwick, H. Chohan, C. Simonet, A. Shrag, A. Noyce (London, United Kingdom)

  • An Open-Access Model for Parkinson’s Disease Progression

    S. Mosovsky, K. Saboo, K. Severson, A. Amini, L. Crawford, N. Yates, J. Adibi, L. Chahine (Pittsburgh, USA)

  • An SNCA triplication in a Kazakhstani patient with young-onset Parkinson’s disease

    R. Kaiyrzhanov, C. Shashkin, N. Zharkinbekova, V. Akhmetzhanov, Z. Myrzayev, A. Karimova, S. Aidarov, K. Mok, H. Houlden (Shymkent, Kazakhstan)

  • An uncommon task specific dystonia masquerading as Myasthenia Gravis

    R. Robinson, J. Mcconville, J. Craig, K. Doherty (Belfast, United Kingdom)

  • Analysis of a wearable sensor, STAT-on®, to detect motor complications in patients with Parkinson´s disease (PDp)

    J. Parra Serrano, MI. Morales Casado, N. Lopez Ariztegui (Toledo, Spain)

  • Analysis of excessive daytime sleepiness and clinical findings in Parkinson’s disease

    S. Ueno, N. Nishikawa, H. Takeshige-Amano, T. Ogawa, D. Kamiyama, A. Shindo, K. Shiina, K. Ishikawa, T. Tsunemi, M. Yoshitake, C. Abe, S. Saiki, T. Hatano, N. Hattori (Tokyo, Japan)

  • Analysis of functional connectivity using machine learning and deep learning in EEG data from patients with focal dystonia

    C. Alves, A. Paulo, D. de Faria, J. Sato, S. Azevedo Silva, V. Borges, H. Ferraz, F. Rodrigues, C. Thielemann, P. Carvalho Aguiar (Sao Carlos Pinhal, Brazil)

  • Analysis of levodopa use in patients with Parkinson’s Disease during pregnancy: a systematic review of the last twenty years

    R. Albuquerque, E. Almeida, G. Herwig, G. Bolner, G. Maia, G. Mantovani, MF. Felippe, V. Müller (Porto Alegre, Brazil)

  • Analysis of subthalamic-nuclei deep brain stimulation using radiomic feature-manifestations: a quantitative approach

    V. Rama Raju (Hyderabad, India)

  • Analysis of the network of genes related to Parkinson’s and identification of key proteins

    H. Ghapani, D. Morshedi, S. Parsafar, F. Aliakbari (Tehran, Islamic Republic of Iran)

  • Analysis of the relationship between acoustic measures and VHI score

    Y. Manor, Y. Kochetkov, Y. Hauptman, D. Shpunt, A. Zait, T. Gurevich (Tel Aviv, Israel)

  • Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy

    M. Werner, E. Bertin, A. Simmonet, E. Noé, P. Fernagut, J. Molina, K. Lowe, E. Bezard, J. Kordower (Atlanta, USA)

  • Analysis of the therapeutic potential of IkT-148009 in Parkinson’s disease

    M. Werner, R. Rush, T. Kelly, S. Singh, S. Kruger, C. Olanow, A. Mcgarry (Atlanta, USA)

  • Analysis of α-Synuclein Seed Amplification Assay in Carriers of GBA and LRRK2 Pathogenic Variants

    K. Fraser, A. Mirelman, O. Mabrouk, N. Omer, L. Concha-Marambio, T. Gurevich, A. Bar Shira, M. Gana-Weisz, O. Goldstein, A. Orr-Urtreger, M. Kestenbaum, J. Cedarbaum, T. Dam, J. Shirvan, N. Giladi, D. Graham, R. Alcalay, A. Thaler (Cambridge, USA)

  • Angiotensin II Type 1 (AT1) receptor antagonists as potential candidates for anxiety treatment in Parkinson’s Disease

    S. Bordet, L. Grasso, L. Udovin, G. Chevalier, M. Otero-Losada, F. Capani, S. Perez-Lloret (Buenos Aires, Argentina)

  • Angiotensin-converting enzyme inhibitors prevent pneumonia in patients with Parkinson’s disease

    A. Kim, JY. Joon Yeon (Cheongju-si, Republic of Korea)

  • Anle138b-P1-02: A randomised, double-blinded, placebo-controlled phase 1b study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of the oligomer modulator anle138b in Parkinson´s disease

    J. Levin, N. Singh, S. Melbourne, A. Morgan, C. Carroll, U. Fietzek, S. Ryazanov, A. Leonov, CH. Griesinger, F. Schmidt, D. Weckbecker, K. Prager, T. Matthias, A. Giese (Wendelsheim, Germany)

  • Anodal Transcranial Direct Current Stimulation (tDCS) on sensorimotor cortex in patients with early-onset Parkinson’s Disease: a Pilot Study.

    C. Simonetta, J. Bissacco, M. Conti, V. Ferrari, M. Pierantozzi, C. Salimei, A. Stefani, NB. Mercuri, T. Schirinzi (Roma, Italy)

  • Anodal transcranial direct current stimulation could change the metabolomic profiles of cerebrospinal fluid in Parkinson’s disease

    W. Jang, H-T. Kim (Gangneung, Republic of Korea)

  • Anti-glutamic acid decarboxylase associated encephalitis presenting with new onset movement disorder after COVID-19 infection

    PY. Chen (Taipei, Taiwan)

  • Anti-tremor efficacy of Nabiximols (JZP378) in a rat Model of essential tremor

    S. Loomis, E. Samoylenko, D. Virley, A. Mccreary (Cambridge, United Kingdom)

  • Anxiety in Parkinson’s disease is associated with changes in brain structural connectivity

    G. Carey, R. Viard, R. Lopes, G. Kuchcinski, L. Defebvre, A. Leentjens, K. Dujardin (Lille, France)

  • Apathy and impulsivity co-occur in Huntington’s disease

    L. Morris, K. Horne, L. Paermentier, C. Buchanan, M. Macaskill, D. Myall, M. Husain, R. Roxburgh, T. Anderson, C. Le Heron (Christchurch, New Zealand)

  • Apathy correlated with motor and non-symptoms in de-novo patients with Parkinson’s disease

    S. Lee, S. Jo, J. Lee, S. Chung (Seoul, Republic of Korea)

  • Apathy in Parkinson’s disease: Relation to autonomic symptoms

    A. Ratajska, J. Goetz, L. Zahodne, C. Etheridge, D. Bowers (Gainesville, USA)

  • Apathy, white-matter microstructure, and effort-based decision making in Parkinson’s Disease

    N. Vanegas-Arroyave, C. Leheron, Z. He, S. Lee, E. Huey, Y. Gazes (Houston, USA)

  • APOE-ɛ4 status and cognitive decline after subthalamic nucleus-deep brain stimulation in Parkinson’s disease: preliminary results of the GENEPARK-DBS study

    A. Sánchez-Soblechero, G. Lafuente, S. Pérez, G. Velilla, M. González-Sánchez, E. González-Turiño, J. Suárez, F. Grandas, V. álvarez, B. Dela Casa (Madrid, Spain)

  • Apolipoprotein E e4 genotype affects early motor progression in Parkinson’s disease through an effect on cognition

    M. Gevertzman, A. Hooyman, J. Longhurst, M. Landers (Las Vegas, USA)

  • Apomorphine effects on Parkinson’s disease fluctuation related pain: a pilot study

    P. Alizadeh, V. Bruno, K. Naser, A. Abusarair, B. Achen (Calgary, Canada)

  • Apomorphine sublingual film for OFF episodes in PD: Impact on orthostatic hypotension during dose-optimization

    W. Jost, M. Coelho, M. Fonseca, G. Castilla-Fernández, D. Magalhães, CK. Denecke Muhr (Wolfach, Germany)

  • Apparition of a thalamic hand after focused ultrasound thalamotomy

    C. Comet, J. Cuony, S. Momjian, V. Fleury (Bruxelles, Belgium)

  • Application of multi-parametric diffusion MRI in detecting visual disturbances in advanced Parkinson’s disease population

    K. Shivok, I. Ailes, M. Syed, I. Shelley, A. Alhussein, I. Fayed, T-W. Liang, C. Wu, A. Sharan, F. Mohamed, R. Sergott, L. Krisa, M. Alizadeh (Philadelphia, USA)

  • Applying the COM-B model to identify potential barriers for in-person on-site visits within the Healthy Brain Ageing (HeBA) study in Luxembourg

    L. Vilas Boas, O. Tsurkalenko, T. Marques, E. Thiry, AM. Hanff, R. Krüger, C. Horlings, A. Garrido, C. Vega, S. Schade, P. Mahlknecht, C. Gomes, S. Ghosh, K. Rege, R. Rawal, C. Pauly, D. Mcintyre, K. Seppi, M. Martí, C. Trenkwalder, E. Tolosa, W. Poewe, V. Satagopam, B. Mollenhauer (Strassen, Luxembourg)

  • Are GBA–Parkinson Disease patients’ good candidates for Deep Brain Stimulation? A Longitudinal Multicentric study on a Large Italian Cohort

    M. Avenali, R. Zangaglia, G. Cuconato, I. Palmieri, A. Albanese, CA. Artusi, M. Bozzali, F. Cavallieri, R. Cilia, A. Cocco, R. Eleopra, A. Imarisio, G. Imbalzano, C. Ledda, L. Lopiano, M. Malaguti, F. Mameli, P. Mitrotti, F. Spagnolo, C. Tassorelli, F. Valentino, F. Valzania, A. Di Fonzo, C. Pacchetti, EM. Valente (Pavia, Italy)

  • Are GDNF receptors the gatekeepers of GDNF efficacy during progressive nigrostriatal neuron loss?

    M. Salvatore, E. Kasanga, Y. Han, R. Mcmanus, W. Navarrete, V. Nejtek, J. Richardson (Fort Worth, USA)

  • Are patients presenting earlier in time? Secular changes in REM sleep behavior disorder

    S. Joza, A. Stefani, A. Iranzo, J. Montplaisir, B. Högl, A. Pelletier, A. Ibrahim, JF. Gagnon, R. Postuma (Montreal, Canada)

  • Argentine Translation and Adaptation of the Scale for the Assessment and Classification of Ataxia (SARA)

    J. Fernández Boccazzi, N. Gonzalez Rojas, M. Cesarini, G. da Prat, J. Etcheverry, E. Gatto (Buenos Aires, Argentina)

  • Arm swing deviations in patients with PD at different gait velocities

    S. Mainka, G. Ebersbach (Beelitz-Heilstaetten, Germany)

  • Artificial intelligence for the improvement of imaging biomarkers in Parkinson’s disease

    V. Dzialas, E. Doering, K. Simonyan, A. Strafella, D. Vaillancourt, T. van Eimeren (Cologne, Germany)

  • Artificial Intelligence to detect and classify tremors in patients with Parkinson’s disease and related conditions

    T. Elshourbagy, M. Hernandez, G. Mckay, J. Brasic (Cairo, Egypt)

  • Asian LRRK2 variants do not increase Likelihood Ratios derived from MDS prodromal Parkinson’s Disease criteria in a community population

    R. Chen, C. Chai, N. Chia, S. Ng, E. Ng, E. Tan, Z. Xu, L. Tan (Singapore, Singapore)

  • Aspects of early detection of parkinson`s disease in ambulatory settings

    R. Matmurodov, B. Muminov, E. Abduqodirov, H. Daminova, K. Khalimova, O. Naimov, R. Juraev (Tashkent, Uzbekistan)

  • Assessing akinesia domains during multitasking in Parkinson’s disease

    V. Dzialas, M. Banwinkler, M. Höhnig, T. van Eimeren (Cologne, Germany)

  • Assessing Gait Disturbances in Parkinson’s Disease Using Multi-Spectral Diffusion Weighted Imaging

    I. Shelley, I. Ailes, M. Syed, K. Shivok, J. Miao, L. Krisa, F. Mohamed, R. Sergott, T. Liang, A. Sharan, M. Kogan, C. Wu, M. Alizadeh, O. Shoraka (Philadelphia, USA)

  • Assessing non-motor symptoms and associations with quality of life among patients in Korle-Bu Teaching Hospital, Ghana

    D. Brodie-Mends, F. Duodu, K. Nkromah, A. Akpalu (Accra, Ghana)

  • Assessing the optimal pallidal target in deep brain stimulation for Parkinson’s disease: A single-center retrospective review

    D. Schumacher, D. Paulo, D. Doss, S. Narasimhan, L. Rui, D. Benoit, D. Englot, A. Giritharan (Nashville, USA)

  • Assessing the swallow tail sign in clinical practice

    MA. Ruiz Yanzi, E. Natera-Villalba, JA. Pineda-Pardo, M. Matarazzo (Madrid, Spain)

  • Assessment of non-motor symptoms of Parkinson’s disease after the repeated courses of the autologous stem cell therapy

    V. Chyzhyk, A. Boika, V. Ponomarev (Minsk, Belarus)

  • Assessment of variation in α-synuclein seed amplification assay results in the PPMI cohort: Association with hyposmia

    A. Siderowf, L. Concha-Marambio, D. Lafontant, R. Alcalay, L. Chahine, T. Faroud, D. Galasko, K. Kieburt, K. Merchant, B. Mollenhauer, K. Poston, J. Seibyl, C. Tanner, T. Simuni, D. Weintraub, A. Videnovic, S. Choi, C. Caspell-Garcia, C. Coffey, M. Frasier, L. Oliveira, S. Hutten, T. Sherer, C. Soto, K. Marek (Philadelphia, USA)

  • Association between Adherence to Physical Activity Guidelines and Health Literacy in Patients with Parkinson’s Disease: An Online Web Survey

    K. Nagaki, T. Mishima, K. Kurihara, S. Fujioka, Y. Tsuboi (Fukuoka-shi, Japan)

  • Association Between Anticholinergic Burden, MCI, and Cholinergic Denervation

    R. Paalanen, S. Roytman, P. Kanel, N. Bohnen (Ann Arbor, USA)

  • Association Between Antiepileptic Drugs and Subsequent Parkinson’s Disease in East London

    Q. Zhang, J. Bestwick, R. Dobson, C. Marshall, A. Noyce (London, United Kingdom)

  • Association between changes in hippocampal volumes, cognition, and CSF markers in Parkinson’s Disease

    S. Becker, O. Granert, C. Schulte, K. Brockmann, B. Roeben, M. Bode, M. Timmers, K. Scheffler, W. Maetzler, D. Berg, I. Liepelt-Scarfone (Calgary, Canada)

  • Association between dysphagia and body mass index and his impact on the severity of anxiety in patients with Parkinson Disease

    EC. Santiago, AJ. Hernández Medrano, MA. Ruiz Mafud, AA. Herrera Ruiz, DR. Aguilar Godinez, LG. Lira Juárez, MA. Medrano Delgado, AM. Regalado Mustafá, A. Domínguez García, G. Hernandez Armesto, DP. Romero Terán, K. Talavera Lagunas, MF. Medina-Pérez, JF. García Hernández, A. Abundes-Corona, GI. Cerda Hernández, M. Rodríguez-Violante, A. Cervantes-Arriaga (MÉXICO, Mexico)

  • Association between fine motor function and brain structure: Findings from the population-based Rhineland Study

    X. Yang, S. Estrada, M. Breteler, N. Aziz (Bonn, Germany)

  • Association between lifestyle and environmental factors with disease severity and age at onset in multi-ethnic Malaysian Parkinson’s disease patients

    JP. Schee, HC. Ting, ZL. Loo, AMF. Dy Closas, TS. Toh, JW. Hor, YW. Tay, JL. Lim, LC. Lit, AH. Tan, SY. Lim (Kuala Lumpur, Malaysia)

  • Association between Parkinson’s Disease and Atrial Fibrillation: A Literature Review

    W. Lintiso, N. Smati, E. Shamim (Gaithersburg, USA)

  • Association between severity of freezing of gait and turning characteristics in Parkinson’s disease

    SM. Cheon, JW. Kim (BUSAN, Republic of Korea)

  • Association between Stress and Bruxism in Egyptian University Female Students Throughout Their Final Exam Period

    MYA. Amine, U. Dakrory (Giza, Egypt)

  • Association between subjective and objective language measures in DBS candidates

    T. Turner, L. Blackett, F. Rodriguez-Porcel (Charleston, USA)

  • Association between supine hypertension and plasma free triiodothyronine in drug-naïve Parkinson’s disease

    T. Umehara, T. Kokubu, J. Takahashi, T. Shiraishi, T. Sato, A. Onda, I. Iguchi (Tokyo, Japan)

  • Association between type 2 diabetes mellitus with parkinson’s disease and the increase of the severity of depression and anxiety in a mexican population

    AA. Herrera Ruiz, DR. Aguila Godinez, AJ. Hernández-Medrano, MA. Ruiz Mafud, A. Abundes-Corona, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)

  • Association of Early and late age of onset with Mitochondrial DNA haplogroup in Indian Spinocerebellar Ataxia type- 2 patients.

    A. Sonakar, M. Srivastava, M. Faruq, A. Srivastava (NEW DELHI, India)

  • Association of fecal short-chain fatty acids with clinical severity and gut microbiota in Essential tremor and its differences from Parkinson’s disease

    P. Huang, PC. Zhang, SD. Chen, YY. Tan (Shanghai, China)

  • Association of Increased Frontal White Matter A2A Receptor Availability with Decreased Frontal Gray Matter Volume in Patients with Parkinson’s Disease

    I. Waggan, E. Rissanen, J. Tuisku, M. Matilainen, R. Parkkola, J. Rinne, L. Airas (Turku, Finland)

  • Association of NOTCH2NLC repeat expansions with dystonia

    J. Lin, C. Li, Q. Jiang, D. Pang, R. Ou, Q. Wei, Y. Hou, L. Zhang, H. Shang (Chengdu, China)

  • Association of real-world wearable mobility measures with Parkinson’s disease severity and disease progression

    A. Mirelman, J. Volkov, A. Solomon, E. Gazit, A. Nieuwboer, S. Del Din, L. Rochester, L. Avanzino, E. Pelosin, B. Bloem, U. Della Croce, A. Cereatti, A. Thaler, J. Shirvan, J. Cedarbaum, N. Giladi, J. Hausdorff (Tel Aviv, Israel)

  • Association of sex with health-related quality of life in adults with chronic tic disorders

    H. Arnold, H. Riordan, D. Claassen, D. Isaacs (Nashville, USA)

  • Association of vestibular disorders with autonomic dysfunction in Parkinson’s Disease

    O. Alenikova, M. Leshkovich (Minsk, Belarus)

  • Associations between non-motor symptoms and patient characteristics in Parkinson’s disease: A multicenter cross-sectional study

    R. Morimoto, M. Iijima, Y. Okuma, K. Suzuki, F. Yoshii, S. Nogawa, T. Osada, K. Kitagawa (Tokyo, Japan)

  • Associations of IL-1β and IL-6 gene polymorphisms with Parkinson’s disease(PD)

    M. Ben Mahmoud, S. Fray, H. Jamoussi, N. Ben Ali, M. Fredj, S. Fezai (Tunis)

  • Asymmetric and profound nigrostriatal dopaminergic dysfunction in Parkinson’s disease with preceding REM sleep behavior disorders

    KA. Woo, HJ. Chang, JY. Joo, JH. Shin, SY. Kim, SM. Lee, BR. Jin, HY. Jeon, HJ. Kim, B. Jeon (Seoul, Republic of Korea)

  • Asymmetric synaptic density and glucose consumption in subjects with non-demented Parkinson’s Disease, as measured with [11C]UCB-J and [18F]FDG PET.

    K. Andersen, A. Hansen, J. Horsager, K. Knudsen, P. Borghammer (Aarhus, Denmark)

  • Asymmetry and side concordance of rest tremor and bradykinesia in patients with essential tremor

    L. Angelini, G. Paparella, D. Costa, D. Birreci, A. Cannavacciuolo, M. Passaretti, D. Colella, A. Berardelli, M. Bologna (Rome, Italy)

  • Asymmetry and the development of phase-specific deep brain stimulation for essential tremor

    S. He, A. Deli, T. West, F. Plazas, A. Pogosyan, C. Wiest, D. Herz, P. Andrade, V. Visser-Vandewalle, E. Pereira, A. Green, H. Tan, H. Cagnan (Oxford, United Kingdom)

  • Asymmetry of striatal dopaminergic function in essential tremor is associated with kinetic tremor asymmetry

    A. Kuusela, E. Honkanen, E. Jaakkola, E. Mäkinen, M. Eklund, S. Nuuttila, K-M. Murtomäki, T. Mertsalmi, T. Noponen, J. Joutsa, F. Scheperjans, V. Kaasinen (Turku, Finland)

  • Asymptomatic Gaucher disease presented as Parkinsonism in 61 years old patient.

    E. Basha, E. Ranxha, J. Tana (Tirana, Albania)

  • At-home adaptive deep brain stimulation improves motor fluctuations and quality of life in patients with Parkinson’s disease: a single-blind randomized study

    C. Oehrn, S. Cernera, L. Hammer, M. Shcherbakova, J. Yao, A. Hahn, C. Smyth, S. Little, P. Starr (San Francisco, USA)

  • Ataxia, deafness, aphonia associated with ANNA-1/ /”anti-Hu” and LUZP4 antibodies

    R. Vasireddy, M. Thandampallayam, P. Sudhakar, Z. Guduru (Lexington, USA)

  • atrophy of cranial nerves v and viii is a hallmark of rfc1-related disorder

    C. Lobo, G. Wertheimer, T. Rezende, PC. Matos, L. Branco, J. Silva, F. Borba, O. Barsottini, JL. Pedroso, W. Marques Jr, M. França Jr (Campinas, Brazil)

  • Atypical Manifestations of Subacute Sclerosing Panencephalitis (SSPE): A Case Series from India

    G. Harikrishna, K. Mala, SK. Kodapala (MANDYA, India)

  • Atypical Parkinsonian Syndrome with evocative brain MRI imaging. About seven cases.

    CH. Boukadir, F. Ferrat, S. Ouardi, S. Bouchaour, M. Boukhalfa, L. Kasmi, M. Akareb, S. Bahlali, W. Amer Elkhedoud (Ben Aknoun, Algiers, Algeria)

  • Atypical parkinsonism and psychiatric disorder in hereditary diffuse leukoencephalopathy with spheroids: a novel variant in the CSF1R gene

    M. Gea, B. Flores-Pina, D. Vilas-Rolan, A. Castillo-Gandia, C. Carrato-Moñino, K. Beyer, M. Paré-Curell, A. Massuet, L. Ispierto-González (Badalona, Spain)

  • Atypical parkinsonism syndromes: clinical presentations

    A. Gunduz, S. Akkus, FZ. Calikusu, E. Koçhan Kızılkılıç, B. Poyraz, A. Altunç, G. Kızıltan (Istanbul, Turkey)

  • Atypical progression of motor symptoms in Facio-Scapulo-Humeral Dystrophy: clinical worsening or overlap?

    D. Calisi, M. de Rosa, M. Russo, A. Thomas, M. Onofrj, S. Sensi (Chieti, Italy)

  • Autoantibody-negative but probable autoimmune hyperreflexia myoclonus syndrome: a case report

    S. Okubo, A. Kimura, N. Nagata, N. Kanazawa, K. Nishiyama, J. Dalmau, T. Iizuka (Kanagawa, Japan)

  • Autoimmune Chorea. Therapy with Monoclonal Antibodies: Experimental and Clinical Approach

    D. Labunskiy, S. Kiryukhina, D. Kuzmin, V. Podsevatkin (Saransk, Russian Federation)

  • Autoimmune encephalitis due to antiglycine antibodies presenting as corticobasal syndrome

    S. Secades (Madrid, Spain)

  • Automated parcellation of the cerebellum in patients with newly diagnosed Parkinson’s disease

    B. Facer, C. de Bezenac, A. Macerollo, T. Butts, R. Sadavarte, J. Farah, S. Keller (Liverpool, United Kingdom)

  • Automated VMAT2 [18F]AV-133 PET analysis in Parkinson’s disease

    R. Manber, B. Brito Vega, C. Mcginnity (London, United Kingdom)

  • Automatic assessment of tic expression using selfie-video

    Y. Loewenstern, N. Benaroya-Milshtein, I. Bar-Gad (Ramat-Gan, Israel)

  • Automatic cluster analysis using semantic relatedness for verbal fluency tasks in Parkinson’s disease

    T. Hähnel, T. Feige, J. Kunze, A. Epler, A. Frank, J. Bendig, N. Schnalke, M. Wolz, P. Themann, B. Falkenburger (Dresden, Germany)

  • Automatic Detection of Parkinson’s Disease by Voice Analysis

    NY. Ryoo, SY. Kim, YC. Youn (Seoul, Republic of Korea)

  • Autonomic dysfunction in the early stages of atypical Parkinsonism would have the first approach in the diagnosis: A report of fifteen cases in the Mexican population.

    DAN. Rebolledo Garcia, XEL. Dominguez Vega, MAR. Briseño Godinez, CAR. Quintero Flores (Mexico, Mexico)

  • Autosomal dominant Parkinson’s disease caused by SNCA p.E46K variant in family with Russian ancestry: A case report

    K. Senkevich, I. Miliukhina, A. Zhuravlev, M. Shumilova, M. Beletskaia, A. Tyurin, M. Grunina, A. Rybakov, J. Ahmad, F. Asayesh, A. Timofeeva, Z. Gan-Or, A. Emelyanov, S. Pchelina (Montreal, Canada)

  • Autosomal recessive Primary Familial Brain Calcification caused by MYORG mutations. Two unrelated cases from the south of Chile

    E. Fernandez, P. Meza, P. Saffie (Concepción, Chile)

  • Axial impairment and bradykinesia are related to increased CSF sTREM2, a neuroinflammation biomarker, in Parkinson’s disease

    A. Brück, R. Ajalin, H. Al-Abdulrasul, H. Zetterberg, K. Blennow, E. Löyttyniemi, J. Rinne (Turku, Finland)

  • Axial tremor response to tractography-defined focused ultrasound thalamotomy for essential tremor: a prospective study

    C. Ribacoba Díaz, A. Fernández Revuelta, M. Yus Fuertes, C. Pérez García, E. López Valdés, R. García Ramos (Madrid, Spain)

  • Axon terminal hypertrophy of striatal projection neurons with levodopa-induced dyskinesia priming

    T. Nakamura, H. Nishijima, F. Mori, I. Kinoshita, T. Kon, C. Suzuki, K. Wakabayashi, M. Tomiyama (Hirosaki, Japan)

Jump to:  View All • [a] b c d e f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley